For example, genetic modification of tumor specific CD4 and CD8 T cells to overexpress phosphoenolpyruvate carboxykinase 1 (PCK1) increased the production of the glycolytic metabolite phosphoenolpyruvate, resulted in increased T cell glycolysis, increased T cell effector function, and restricted tumor growth and prolonged survival in a melanoma mouse model [22]. This evidence concerns the gene CD8A and neoplasm.